IRIS Accounts Production v24.2.0.383 01629616 Board of Directors 1.4.23 31.3.24 31.3.24 0 0 false true false false true false Fair value model iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh016296162023-03-31016296162024-03-31016296162023-04-012024-03-31016296162022-03-31016296162022-04-012023-03-31016296162023-03-3101629616ns15:EnglandWales2023-04-012024-03-3101629616ns14:PoundSterling2023-04-012024-03-3101629616ns10:Director12023-04-012024-03-3101629616ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3101629616ns10:SmallEntities2023-04-012024-03-3101629616ns10:AuditExempt-NoAccountantsReport2023-04-012024-03-3101629616ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3101629616ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3101629616ns10:FullAccounts2023-04-012024-03-3101629616ns10:Director22023-04-012024-03-3101629616ns10:RegisteredOffice2023-04-012024-03-3101629616ns5:CurrentFinancialInstruments2024-03-3101629616ns5:CurrentFinancialInstruments2023-03-3101629616ns5:ShareCapital2024-03-3101629616ns5:ShareCapital2023-03-3101629616ns5:FurtherSpecificReserve1ComponentTotalEquity2024-03-3101629616ns5:FurtherSpecificReserve1ComponentTotalEquity2023-03-3101629616ns5:RetainedEarningsAccumulatedLosses2024-03-3101629616ns5:RetainedEarningsAccumulatedLosses2023-03-3101629616ns5:PlantMachinery2023-04-012024-03-3101629616ns5:PlantMachinery2023-03-3101629616ns5:PlantMachinery2024-03-3101629616ns5:PlantMachinery2023-03-3101629616ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-03-3101629616ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-03-31
REGISTERED NUMBER: 01629616 (England and Wales)












MEDICAL PROPERTY DEVELOPMENTS LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024






MEDICAL PROPERTY DEVELOPMENTS LIMITED (REGISTERED NUMBER: 01629616)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


MEDICAL PROPERTY DEVELOPMENTS LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 MARCH 2024







DIRECTORS: P A Bauchop
Mrs D Bauchop



REGISTERED OFFICE: Tanglewood
Cowes Lane
Hook Park
Southampton
Hampshire
SO31 9HD



REGISTERED NUMBER: 01629616 (England and Wales)



BANKERS: Bank of Scotland
33 Old Broad Street
London
BX2 1LB

MEDICAL PROPERTY DEVELOPMENTS LIMITED (REGISTERED NUMBER: 01629616)

BALANCE SHEET
31 MARCH 2024

2024 2023
Notes £ £
FIXED ASSETS
Tangible assets 4 1,030 1,297
Investment property 5 1,820,000 1,520,000
1,821,030 1,521,297

CURRENT ASSETS
Debtors 6 35,047 41,325
Cash at bank 28,997 64,538
64,044 105,863
CREDITORS
Amounts falling due within one year 7 (79,391 ) (123,877 )
NET CURRENT LIABILITIES (15,347 ) (18,014 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,805,683

1,503,283

PROVISIONS FOR LIABILITIES (177,352 ) (102,352 )
NET ASSETS 1,628,331 1,400,931

CAPITAL AND RESERVES
Called up share capital 1,200 1,200
Non-
distributable
reserve 989,023 764,023
Retained earnings 638,108 635,708
SHAREHOLDERS' FUNDS 1,628,331 1,400,931

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

MEDICAL PROPERTY DEVELOPMENTS LIMITED (REGISTERED NUMBER: 01629616)

BALANCE SHEET - continued
31 MARCH 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 15 August 2024 and were signed on its behalf by:





P A Bauchop - Director


MEDICAL PROPERTY DEVELOPMENTS LIMITED (REGISTERED NUMBER: 01629616)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024


1. STATUTORY INFORMATION

Medical Property Developments Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with "The Financial Reporting Standards applicable in the UK and Republic of Ireland" ("FRS 102") and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £1.

The financial statements have been prepared under the historical cost convention, modified to include certain financial instruments at fair value. The principal accounting policies adopted are set out below.

Turnover
Turnover represents rents receivable in the year.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.
Computer Equipment - Straight line over 5 years

Investment property
Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss.

Equity instruments
Equity instruments issued by the company are recorded at the fair value of the proceeds received net of direct issue costs. Dividend's payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

Financial assets
The Company has elected to apply the provision of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial assets are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

Basic financial assets, which include trade and other receivables and cash and bank balances are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method, unless the arrangement constitutes a financial transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Financial liabilities
Basic financial liabilities which include trade and other payables, are initially measured at transaction price and subsequently measured at amortised cost, unless the arrangement constitutes a financing transaction where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest.

MEDICAL PROPERTY DEVELOPMENTS LIMITED (REGISTERED NUMBER: 01629616)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024


3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2023 - NIL).

4. TANGIBLE FIXED ASSETS
Computer
Equipment
£
COST
At 1 April 2023
and 31 March 2024 3,142
DEPRECIATION
At 1 April 2023 1,845
Charge for year 267
At 31 March 2024 2,112
NET BOOK VALUE
At 31 March 2024 1,030
At 31 March 2023 1,297

5. INVESTMENT PROPERTY
Total
£
FAIR VALUE
At 1 April 2023 1,520,000
Revaluations 300,000
At 31 March 2024 1,820,000
NET BOOK VALUE
At 31 March 2024 1,820,000
At 31 March 2023 1,520,000

Fair value at 31 March 2024 is represented by:
£
Valuation in 2001 150,814
Valuation in 2004 4,421
Valuation in 2005 75,000
Valuation in 2006 85,000
Valuation in 2007 41,716
Valuation in 2008 (44,250 )
Valuation in 2010 2,781
Valuation in 2011 250,000
Valuation in 2016 320,000
Valuation in 2024 300,000
Cost 634,518
1,820,000

MEDICAL PROPERTY DEVELOPMENTS LIMITED (REGISTERED NUMBER: 01629616)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024


5. INVESTMENT PROPERTY - continued

If investment properties had not been revalued they would have been included at the following historical cost:

2024 2023
£ £
Cost 634,518 634,518

Investment properties were valued on a fair value basis on 31 March 2024 by P A Bauchop, Director .

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£ £
Other debtors 35,047 41,325

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£ £
Taxation and social security 19,561 28,092
Other creditors 59,830 95,785
79,391 123,877